Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Journal of Diabetes · 2024
DOI: 10.1111/1753-0407.13609 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes, 2024. Verfasst von Richard J MacIsaac und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk, Servier, Medtronic.
Abstract (Originalsprache)
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of the GLP‐1RA class of medications has been derived from kidney‐related outcomes reported from cardiovascular outcome trials (CVOTs). GLP‐1RAs have been shown to reduce albuminuria, mitigate cardiovascular risk, and possibly attenuate estimated glomerular filtration rate (eGFR) decline. The kidney‐protective effects of GLP‐1RAs are thought to be attributed to their anti‐inflammatory, antioxidant, and vasodilatory properties. Despite these promising findings, the use of GLP‐RAs has yet to be definitively shown to slow progression to chronic kidney failure in people with T2DM. The Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) is the first major trial assessing the potential of a GLP‐1RA to slow progression of kidney disease in people with established CKD to clinically important kidney end points. On March 5, 2024, the top line result from FLOW was announced with semaglutide 1.0 mg being reported to reduce the primary end point of the trial by a significant 24% compared with placebo. Here, we summarize the kidney outcomes reported from CVOTs for the GLP‐1RA class of medication and briefly describe kidney outcomes from other major GLP‐1RAs trials. We also discuss a potential role of the dual GLP‐1/glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, as a kidney‐protective agent. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
- Department of Medicine St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Victoria, Australia.
- Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia.
- Department of Endocrinology, Austin Health, Melbourne, Australia.
- Department of Medicine, Austin Health, Melbourne Medical School, Parkville, Victoria, Australia.
ORCID-Profile: Richard J MacIsaac, Philippa Trevella, Elif I Ekinci
Förderung
- Novo Nordisk
- Servier
- Medtronic
- The Rebecca Cooper Medical Research Foundation
- St Vincent's Research Foundation
- The Juvenile Diabetes Research Foundation (T1D)
- Gray Innovations
- The Diabetes Australia Research Trust/Program
Zitieren
APA
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024). Glucagon‐like peptide‐1 receptor agonists and kidney outcomes. Journal of Diabetes. https://doi.org/10.1111/1753-0407.13609
Vancouver
MacIsaac RJ, Trevella P, Ekinci EI. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes. Journal of Diabetes. 2024. doi:10.1111/1753-0407.13609
BibTeX
@article{MacIsaac2024,
author = {MacIsaac, Richard J and Trevella, Philippa and Ekinci, Elif I},
title = {Glucagon‐like peptide‐1 receptor agonists and kidney outcomes},
journal = {Journal of Diabetes},
year = {2024},
doi = {10.1111/1753-0407.13609}
}
EUVIMED